The purpose of this legislation is to enhance the reforms related to drug pricing established in the Inflation Reduction Act. It aims to make prescription medications more affordable for Medicare beneficiaries by improving the process for negotiating drug prices. Key provisions of the legislation include several changes to how drugs are selected for negotiation and how their prices are determined. First, it increases the number of drugs eligible for negotiation from 15 to 50 starting in 2028.